To explore ATAD2 alterations in detail for endometrial cancer, putative copy-number alterations (GISTIC-based analysis [17]), showed a highly significant correlation of increased copy-number levels and mRNA expression of ATAD2 for endometrial cancer, confirming previous findings that ATAD2 amplification leads to higher expression of ATAD2 (Supplementary Figure S1A). The gene discussed is ATAD2; the disease is endometrial cancer.